Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 106, Issue 5, 2011, Pages 884-893

  Fontana, Robert J ^a   Sanyal, Arun J ^b   Ghany, Marc G ^c   Bonkovsky, Herbert L ^d,e   Morgan, Timothy R ^f,g   Litman, Heather J ^h   Reid, Andrea E ⁱ   Lee, William M ^j   Naishadham, Deepa ^h  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^e CAROLINAS MEDICAL CENTER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^h NEW ENGLAND RESEARCH INSTITUTES   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEGINTERFERON ALPHA2A; PROTON PUMP INHIBITOR; RIBAVIRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; ENDOSCOPY; FEMALE; FOLLOW UP; HEPATITIS C; HOMEOSTASIS; HUMAN; INCIDENCE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; STOMACH DISEASE;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; ESOPHAGEAL AND GASTRIC VARICES; HEPATITIS C, CHRONIC; HUMANS; HYPERTENSION, PORTAL; INTERFERON ALFA-2A; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; STOMACH DISEASES;

EID: 79955623436     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2010.456     Document Type: Article

References (27)

1. Carpinelli C, Primignani M, Preatoni P et al. Portal hypertensive gastropathy: reproducibility of a classification, prevalence of elementary lesions, sensitivity and specificity in the diagnosis of cirrhosis of the liver. A NIEC multicenter study. Ital J Gastroenterol 1997; 29: 533-540. (Pubitemid 128729299)
2. Sarin SK. Diagnostic issues: portal hypertensive gastropathy and gastric varices. In: DeFranchis R (ed). Portal Hypertension II. Proceedings of the Second Baveno International Consensus Workshop on Definitions, Methodology and Therapeutic Strategies. Blackwell Science: Oxford, 1996, pp, 30-55.
3. Payen JL, Cales P, Voigt JJ et al. Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology 1995; 108: 134-144.
4. Merli M, Nicolini G, Angeloni S et al. The natural history of portal hypertensive gastropathy in patients with liver cirrhosis and mild portal hypertension. Am J Gastroenterol 2004; 99: 1959-1965. (Pubitemid 39421239)
5. Primignani M, Carpinelli L, Preatoni P et al. Natural history of portal hypertensive gastropathy in patients with liver cirrhosis. Gastroenterology 2000; 119: 181-7. (Pubitemid 30452591)
6. Gostout CJ, Viggiano TR, Balm RK. Acute gastrointestinal bleeding from portal hypertensive gastropathy: prevalence and clinical features. Am J Gastroenterol 1993; 88: 2030-2033. (Pubitemid 23352166)
7. Kinjo N, Kawanaka H, Akahoshi T et al. Significance of ERK nitration in portal hypertensive gastropathy and its therapeutic implications. Am J Physiol 2008; 295: G1016-24.
8. Perini RF, Camara PRS, Ferraz JGP. Pathogenesis of portal hypertensive gastropathy: translating basic research into clinical practice. Nat Clin Pract Gastroenterol Hepatol 2009; 6: 150-8.
9. DiBisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low dose peginterferon. N Engl J Med 2008; 359: 2429-2441.
10. Fartoux L, Degos F, Trepo C et al. Effect of prolonged interferon therapy on the outcome of hepatitis C virus-related cirrhosis: a randomized trial. Clinic Gastroenterol & Hepatology 2007; 5: 502-7. (Pubitemid 46575357)
11. Afdhal NH, Levine R, Brown R et al. Colchicine versus peginterferon alfa-2b long term therapy: results of the 4 year CoPilot trial (abstract). J Hepatol 2008; 48: S4.
12. Bruix J, Poynard T, Colombo M et al. Final results of the EPIC3 Cirrhosis Maintenance Trial: pegintron maintenance therapy in cirrhotic (METAVIR F4) HCV patients, who failed to respond to interferon/ribavirin therapy. Gastroenterology 2009 (Abstract) 136 (Suppl 1): 295.
13. Roberts S, Gordon A, McLean C et al. Effect of sustained viral response on hepatic venous pressure gradient in hepatitis-C related cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 932-7. (Pubitemid 47127019)
14. Rincon D, Ripoll C, LoIacono O et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006; 101: 2269-2274. (Pubitemid 44477554)
15. Fontana RJ, Sanyal AJ, Mehta S et al. Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial. Am J Gastroenterol 2006; 101: 1-10.
16. Sanyal AJ, Fontana RJ, DiBisceglie AM et al. The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc 2006; 64: 855-864. (Pubitemid 44829826)
17. Kumar A, Mishra SR, Sharma P et al. Clinical, laboratory, and hemodynamic parameters in portal hypertensive gastropathy. A study of 254 cirrhotics. J Clin Gastroenterol 2010; 44: 294-300.
18. Sarin SK, Shahi H, Jain M et al. The natural history of portal hypertensive gastropathy: influence of variceal eradication. Am J Gastroenterol 2000; 95: 2888-2899.
19. Sarin SK, Sreenivas DV, Lahoti D et al. Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology 1992; 101: 994-9.
20. Fontana RJ, Sanyal AJ, Ghany MG et al. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010; 138: 2321-2331.
21. Lok ASF, Ghany MG, Goodman ZD et al. Predicting cirrhosis in patients with chronic hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005; 38: 518-526.
22. Sheth SG, Flamm SL, Gordon FD et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998; 93: 44-8. (Pubitemid 29065511)
23. Dore MP, Mura D, Deledda S et al. Active peptic ulcer disease in patients with hepatitis C virus-related cirrhosis. The role of helicobacter pylori infection and portal hypertensive gastropathy. Can J Gastroenterol 2004; 18: 521-4. (Pubitemid 39248253)
24. Stewart CA, Sanyal AJ. Grading portal gastropathy: validation of a gastropathy scoring system. Am J Gastroenterol 2003; 98: 1758-1765. (Pubitemid 36959156)
25. Lepe R, Layden-Almer JE, Layden TJ et al. Ethnic differences in the presentation of chronic hepatitis C. J Viral Hepat 2006; 13: 116-120.
26. Tencate V, Layden-Almer JE, Wolfert M et al. Paired biopsies illustrate racial differences in fibrosis progression in HCV patients (abstract). Hepatology 2009; 50 (Suppl 1): 1629.
27. Kallwitz ER, Layden-Almer J, Dhamija M et al. Ethnicity and body mass index are associated with hepatitis C presentation and progression. Clin Gastroenterol Hepatol 2010; 8: 72-8.